Patents by Inventor Randall Bateman

Randall Bateman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250147049
    Abstract: The present disclosure provides methods to quantify and analyze various CSF Tau species and the use thereof to measure pathological features and/or clinical symptoms of tauopathies, including determining the amount of time to dementia due to Alzheimer's disease, determining the time from dementia onset, staging Alzheimer's disease, guiding treatment decisions, and evaluate the clinical efficacy of certain therapeutic interventions.
    Type: Application
    Filed: January 21, 2022
    Publication date: May 8, 2025
    Inventors: Randall Bateman, Eric McDade, Nicolas Barthelemy, Kanta Horie, Yan Li
  • Publication number: 20250051427
    Abstract: Disclosed herein are antibodies, pharmaceutical formulations for treating or preventing Alzheimer's disease, methods of treating or preventing Alzheimer's disease, and kits comprising pharmaceutical formulations for treating or preventing Alzheimer's Disease comprising an anti-A? protofibril antibody and anti-tau antibody.
    Type: Application
    Filed: November 8, 2022
    Publication date: February 13, 2025
    Inventors: Larisa REYDERMAN, Jin ZHOU, Lynn KRAMER, Michael IRIZARRY, Pallavi SACHDEV, Shobha DHADDA, David LI, Kristin WILDSMITH, Pau ACEVES BALDO, Sumit RAWAL, Akihiko KOYAMA, Chad SWANSON, Michio KANEKIYO, June KAPLOW, David VERBEL, Ishani LANDRY, Seiichi HAYATO, Robert GORDON, Randall BATEMAN, Eric MCDADE
  • Publication number: 20250020669
    Abstract: The present disclosure provides methods to detect and optionally quantify Nfl present in cerebrospinal fluid and blood and use of the methods to detect and optionally measure levels of Nfl biomarkers indicative of neuronal damage. Also disclosed are anti-Nfl antibodies.
    Type: Application
    Filed: February 10, 2022
    Publication date: January 16, 2025
    Inventors: Randall Bateman, Melissa Budelier, David Holtzman, Hong Jiang
  • Patent number: 12066444
    Abstract: The present disclosure provides methods for blood-based examination useful to identify subjects with A? amyloidosis and/or to identify subjects who should or should not undergo further testing or treatment for A? amyloidosis, as well as methods for treating subjects diagnosed with A? amyloidosis by the methods disclosed herein.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: August 20, 2024
    Assignee: Washington University
    Inventor: Randall Bateman
  • Publication number: 20230341421
    Abstract: The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.
    Type: Application
    Filed: April 24, 2023
    Publication date: October 26, 2023
    Inventors: Nicolas Barthelemy, Randall Bateman, Eric McDade
  • Publication number: 20230132508
    Abstract: The present disclosure relates to methods of measuring and analyzing phosphorylation sites in the tau protein and determining correlations with other biomarkers of Alzheimer's disease and tauopathies.
    Type: Application
    Filed: March 31, 2021
    Publication date: May 4, 2023
    Applicants: Genentech Inc., Washington University
    Inventors: Kristin Ruth Wildsmith, Balazs Toth, Randall Bateman, Nicolas Barthelemy
  • Patent number: 11635440
    Abstract: The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.
    Type: Grant
    Filed: June 17, 2022
    Date of Patent: April 25, 2023
    Assignee: Washington University
    Inventors: Nicolas Barthelemy, Randall Bateman, Eric McDade
  • Publication number: 20220317136
    Abstract: The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.
    Type: Application
    Filed: June 17, 2022
    Publication date: October 6, 2022
    Inventors: Nicolas Barthelemy, Randall Bateman, Eric McDade
  • Patent number: 11402392
    Abstract: The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.
    Type: Grant
    Filed: July 6, 2021
    Date of Patent: August 2, 2022
    Assignee: Washington University
    Inventors: Nicolas Barthelemy, Randall Bateman, Eric McDade
  • Publication number: 20220120765
    Abstract: The present disclosure provides methods for blood-based examination useful to identify subjects with A? amyloidosis and/or to identify subjects who should or should not undergo further testing or treatment for A? amyloidosis, as well as methods for treating subjects diagnosed with A? amyloidosis by the methods disclosed herein.
    Type: Application
    Filed: January 9, 2020
    Publication date: April 21, 2022
    Inventors: Melissa Budelier, Randall Bateman
  • Publication number: 20220064271
    Abstract: This invention relates to epitope binding agents that specifically bind to tau and methods of use thereof. The disclosure provides immunoassays, kits, and pharmaceutical compositions which include an epitope binding agent that specifically bind to tau. The disclosure provides methods of reducing the spread of tau aggregates and methods of reducing a tauopathy-related pathology.
    Type: Application
    Filed: September 1, 2021
    Publication date: March 3, 2022
    Inventors: Randall Bateman, David Holtzman, Kanta Horie, Nicolas Barthelemy, Chihiro Sato, Hong Jiang
  • Publication number: 20210341495
    Abstract: The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.
    Type: Application
    Filed: July 6, 2021
    Publication date: November 4, 2021
    Inventors: Nicolas Barthelemy, Randall Bateman, Eric McDade
  • Publication number: 20210255201
    Abstract: The present disclosure provides methods for blood-based examination useful to identify subjects with A? amyloidosis and/or to identify subjects who should or should not undergo further testing or treatment for A? amyloidosis, as well as methods for treating subjects diagnosed with A? amyloidosis by the methods disclosed herein.
    Type: Application
    Filed: May 1, 2018
    Publication date: August 19, 2021
    Inventor: Randall Bateman
  • Patent number: 11085935
    Abstract: The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.
    Type: Grant
    Filed: September 9, 2020
    Date of Patent: August 10, 2021
    Assignee: Washington University
    Inventors: Nicolas Barthelemy, Randall Bateman, Eric McDade
  • Publication number: 20210096139
    Abstract: The invention relates to in vitro methods for measuring the in vivo metabolism of tau in a subject.
    Type: Application
    Filed: September 25, 2020
    Publication date: April 1, 2021
    Inventors: Randall Bateman, Chihiro Sato, Kwasi Mawuenyega, Tim Miller, David Holtzman
  • Publication number: 20200400689
    Abstract: The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.
    Type: Application
    Filed: September 9, 2020
    Publication date: December 24, 2020
    Inventors: Nicolas Barthelemy, Randall Bateman
  • Patent number: 10830775
    Abstract: The invention relates to in vitro methods for measuring the in vivo metabolism of tau in a subject.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: November 10, 2020
    Assignee: Washington University
    Inventors: Randall Bateman, Chihiro Sato, Kwasi Mawuenyega, Tim Miller, David Holtzman
  • Publication number: 20170307639
    Abstract: The invention relates to in vitro methods for measuring the in vivo metabolism of tau in a subject.
    Type: Application
    Filed: September 30, 2015
    Publication date: October 26, 2017
    Applicant: Washington University
    Inventors: Randall Bateman, Chihiro Sato, Kwasi Mawuenyega, Tim Miller, David Holtzman
  • Publication number: 20160178646
    Abstract: The present invention relates to methods of detecting, diagnosing, monitoring, and assessing treatment effects for A? amyloidosis, early in the course of clinical disease or prior to the onset of brain damage and clinical symptoms.
    Type: Application
    Filed: March 1, 2016
    Publication date: June 23, 2016
    Inventors: Randall Bateman, Kwasi Mawuenyega, Vitaliy Ovod, Anna Bareiss, Tom Kasten, David Holtzman
  • Publication number: 20160169916
    Abstract: The present invention relates to methods of diagnosing, monitoring, and assessing treatment effects for A? amyloidosis, early in the course of clinical disease or prior to the onset of brain damage and clinical symptoms. Methods of measuring the in vivo metabolism of biomolecules produced in the CNS in a subject are provided.
    Type: Application
    Filed: February 24, 2016
    Publication date: June 16, 2016
    Inventors: David Holtzman, Randall Bateman, Kwasi G. Mawuenyega